Bicara Therapeutics (BCAX) Accumulated Expenses (2023 - 2026)

Bicara Therapeutics (BCAX) has 4 years of Accumulated Expenses data on file, last reported at $1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses fell 89.42% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (down 89.42% YoY), and the FY2025 full-year result was $1.1 million, down 91.14% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $1.3 million, up from $1.1 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $12.9 million in Q4 2024 and bottomed at $700000.0 in Q3 2025.
• The 4-year median for Accumulated Expenses is $3.8 million (2025), against an average of $5.4 million.
• The widest annual swing landed in 2024, when Accumulated Expenses jumped 59.88%; it then plunged 91.14% in 2025.
• A 4-year view of Accumulated Expenses shows it stood at $8.1 million in 2023, then surged by 59.88% to $12.9 million in 2024, then slumped by 91.14% to $1.1 million in 2025, then climbed by 13.94% to $1.3 million in 2026.
• The last three Accumulated Expenses figures came in at $1.3 million (Q1 2026), $1.1 million (Q4 2025), and $700000.0 (Q3 2025), per Business Quant data.

Peer Comparison